Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Shares Outstanding (Diluted Average) (2019 - 2025)

Harmony Biosciences Holdings' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $58.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 1.17% year-over-year to $58.5 million; the TTM value through Dec 2025 reached $58.5 million, up 1.17%, while the annual FY2025 figure was $58.5 million, 1.17% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $58.5 million at Harmony Biosciences Holdings, roughly flat from $58.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $61.2 million in Q1 2023 and bottomed at $57.6 million in Q2 2024.
  • The 5-year median for Shares Outstanding (Diluted Average) is $58.8 million (2021), against an average of $59.3 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 654.82% in 2021 before it decreased 5.92% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $59.2 million in 2021, then rose by 3.2% to $61.1 million in 2022, then fell by 1.19% to $60.4 million in 2023, then fell by 4.15% to $57.9 million in 2024, then grew by 1.17% to $58.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Shares Outstanding (Diluted Average) are $58.5 million (Q4 2025), $58.7 million (Q3 2025), and $58.5 million (Q2 2025).